Beyonttra (acoramidis)
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- acoramidis
- Company
- Bayer AG
- Status
- Authorised
- Therapeutic area
- Amyloid Neuropathies, Familial
- CHMP opinion
- Thu 12 Dec 2024
- EU approval
- Mon 10 Feb 2025
- Designations
- Additional monitoring
- Application
- EMEA/H/C/006333
- ATC
- C01EB25
- Official record
- www.ema.europa.eu
Indication
For the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
Regulatory milestones
No milestones recorded in the last year.
Follow Beyonttra
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.